Meridian Bioscience, Inc. reported earnings results for the third quarter and nine months ended June 30, 2022. For the third quarter, the company reported sales was USD 67.77 million compared to USD 63.51 million a year ago. Net loss was USD 7.34 million compared to net income of USD 11.67 million a year ago. Basic loss per share from continuing operations was USD 0.17 compared to basic earnings per share from continuing operations of USD 0.27 a year ago.
For the nine months, sales was USD 267.34 million compared to USD 241.69 million a year ago. Net income was USD 36.75 million compared to USD 64.75 million a year ago. Basic earnings per share from continuing operations was USD 0.84 compared to USD 1.5 a year ago. Diluted earnings per share from continuing operations was USD 0.83 compared to USD 1.47 a year ago.